

TDMS No. 99028 - 06  
Test Type: CHRONIC  
Route: SKIN APPLICATION  
Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

bis(2-Chloroethoxy)methane

CAS Number: 111-91-1

Date Report Requested: 08/26/2009

Time Report Requested: 13:44:13

First Dose M/F: 10/03/02 / 10/02/02

Lab: BAT

F1\_M3\_Rev1

**C Number:** C99028  
**Lock Date:** 09/20/2005  
**Cage Range:** ALL  
**Date Range:** ALL  
**Reasons For Removal:** ALL  
**Removal Date Range:** ALL  
**Treatment Groups:** Include ALL  
**Study Gender:** Both  
**TDMSE Version:** 2.1.0

TDMS No. 99028 - 06  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

bis(2-Chloroethoxy)methane

CAS Number: 111-91-1

Date Report Requested: 08/26/2009  
 Time Report Requested: 13:44:13  
 First Dose M/F: 10/03/02 / 10/02/02  
 Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	150 MG/KG	300 MG/KG	600 MG/KG
<b>Disposition Summary</b>				
Animals Initially in Study	50	50	50	50
Early Deaths				
Moribund Sacrifice	7	4	2	8
Natural Death	6	6	6	14
Survivors				
Moribund Sacrifice		1		
Natural Death		1		1
Terminal Sacrifice	37	38	42	27
Animals Examined Microscopically	50	50	50	50

**ALIMENTARY SYSTEM**

Esophagus	(50)	(50)	(50)	(50)
Inflammation			1 (2%)	1 (2%)
Ulcer			1 (2%)	
Gallbladder	(50)	(49)	(49)	(50)
Inflammation				1 (2%)
Intestine Large, Cecum	(50)	(50)	(50)	(50)
Intestine Large, Colon	(50)	(50)	(50)	(50)
Intestine Small, Duodenum	(50)	(50)	(50)	(50)
Epithelium, Necrosis	1 (2%)			
Intestine Small, Ileum	(50)	(50)	(50)	(50)
Intestine Small, Jejunum	(50)	(50)	(50)	(50)
Inflammation				1 (2%)
Mineralization				1 (2%)
Epithelium, Diverticulum				1 (2%)
Peyer's Patch, Hyperplasia	1 (2%)		1 (2%)	1 (2%)
Serosa, Inflammation				1 (2%)
Liver	(50)	(50)	(50)	(50)
Angiectasis		1 (2%)		
Basophilic Focus	3 (6%)	1 (2%)	1 (2%)	3 (6%)
Clear Cell Focus	26 (52%)	29 (58%)	34 (68%)	16 (32%)
Congestion				1 (2%)
Eosinophilic Focus	26 (52%)	28 (56%)	27 (54%)	27 (54%)
Fibrosis			1 (2%)	
Hemorrhage				1 (2%)
Infarct	1 (2%)	2 (4%)		2 (4%)
Inflammation	5 (10%)	3 (6%)	5 (10%)	5 (10%)
Mixed Cell Focus	9 (18%)	9 (18%)	9 (18%)	7 (14%)
Regeneration				1 (2%)
Tension Lipidosis	9 (18%)	1 (2%)	3 (6%)	6 (12%)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99028 - 06  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**  
 bis(2-Chloroethoxy)methane  
 CAS Number: 111-91-1

Date Report Requested: 08/26/2009  
 Time Report Requested: 13:44:13  
 First Dose M/F: 10/03/02 / 10/02/02  
 Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	150 MG/KG	300 MG/KG	600 MG/KG
Thrombosis			2 (4%)	1 (2%)
Bile Duct, Cyst				1 (2%)
Centrilobular, Degeneration				3 (6%)
Hepatocyte, Hypertrophy		1 (2%)		1 (2%)
Hepatocyte, Necrosis	3 (6%)	2 (4%)	10 (20%)	2 (4%)
Hepatocyte, Vacuolization Cytoplasmic, Diffuse	14 (28%)	11 (22%)	12 (24%)	13 (26%)
Oval Cell, Hyperplasia			2 (4%)	
Serosa, Inflammation		1 (2%)		
Mesentery	(5)	(8)	(11)	(1)
Inflammation			3 (27%)	1 (100%)
Necrosis	4 (80%)	7 (88%)	7 (64%)	
Pancreas	(50)	(50)	(50)	(50)
Basophilic Focus	1 (2%)			1 (2%)
Acinus, Atrophy	1 (2%)		1 (2%)	1 (2%)
Acinus, Hyperplasia	8 (16%)	4 (8%)	13 (26%)	2 (4%)
Artery, Inflammation		1 (2%)		
Duct, Cyst		2 (4%)	2 (4%)	2 (4%)
Salivary Glands	(50)	(50)	(50)	(50)
Stomach, Forestomach	(50)	(50)	(50)	(50)
Edema				1 (2%)
Erosion		1 (2%)		1 (2%)
Inflammation	1 (2%)	3 (6%)		2 (4%)
Ulcer	1 (2%)	1 (2%)	1 (2%)	7 (14%)
Epithelium, Hyperplasia		3 (6%)	1 (2%)	2 (4%)
Stomach, Glandular	(50)	(50)	(50)	(50)
Erosion				4 (8%)
Inflammation			1 (2%)	1 (2%)
Glands, Hyperplasia			1 (2%)	
Serosa, Inflammation			1 (2%)	
Tongue	(1)	(0)	(0)	(0)
Mineralization	1 (100%)			
Tooth	(5)	(5)	(4)	(1)
Dysplasia	4 (80%)	4 (80%)		1 (100%)
Inflammation			1 (25%)	
Peridental Tissue, Fibrosis		1 (20%)	2 (50%)	1 (100%)

**CARDIOVASCULAR SYSTEM**

Blood Vessel	(50)	(50)	(50)	(50)
Adventitia, Inflammation			2 (4%)	
Heart	(50)	(50)	(50)	(50)
Artery, Inflammation	2 (4%)		2 (4%)	
Atrium, Thrombosis				1 (2%)
Epicardium, Hyperplasia			1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99028 - 06  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**  
 bis(2-Chloroethoxy)methane  
 CAS Number: 111-91-1

Date Report Requested: 08/26/2009  
 Time Report Requested: 13:44:13  
 First Dose M/F: 10/03/02 / 10/02/02  
 Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	150 MG/KG	300 MG/KG	600 MG/KG
Epicardium, Inflammation	1 (2%)		1 (2%)	
Myocardium, Cardiomyopathy	10 (20%)	12 (24%)	7 (14%)	28 (56%)
Myocardium, Fibrosis		3 (6%)	3 (6%)	13 (26%)
Myocardium, Infiltration Cellular, Mononuclear Cell	11 (22%)	12 (24%)	8 (16%)	28 (56%)
Myocardium, Mineralization		1 (2%)	2 (4%)	3 (6%)
Myocardium, Necrosis	3 (6%)	2 (4%)		1 (2%)
Myocardium, Vacuolization Cytoplasmic	10 (20%)	15 (30%)	11 (22%)	29 (58%)

**ENDOCRINE SYSTEM**

Adrenal Cortex	(49)	(50)	(50)	(50)
Degeneration	1 (2%)			
Hyperplasia	13 (27%)	4 (8%)	11 (22%)	2 (4%)
Hypertrophy	24 (49%)	34 (68%)	26 (52%)	22 (44%)
Subcapsular, Hyperplasia	43 (88%)	44 (88%)	50 (100%)	39 (78%)
Adrenal Medulla	(49)	(50)	(50)	(50)
Hyperplasia		2 (4%)	1 (2%)	
Pigmentation, Melanin				1 (2%)
Islets, Pancreatic	(50)	(50)	(50)	(50)
Hyperplasia	32 (64%)	35 (70%)	39 (78%)	21 (42%)
Parathyroid Gland	(47)	(33)	(45)	(46)
Cyst	1 (2%)			2 (4%)
Pituitary Gland	(50)	(49)	(49)	(49)
Pars Distalis, Cyst	6 (12%)	1 (2%)	3 (6%)	3 (6%)
Pars Distalis, Hyperplasia	20 (40%)	5 (10%)	17 (35%)	5 (10%)
Pars Intermedia, Cyst	1 (2%)			
Thyroid Gland	(50)	(50)	(50)	(50)
Inflammation	1 (2%)			
Follicle, Cyst			2 (4%)	
Follicular Cell, Hyperplasia				2 (4%)

**GENERAL BODY SYSTEM**

None

**GENITAL SYSTEM**

Epididymis	(50)	(50)	(50)	(50)
Atrophy	1 (2%)			
Granuloma Sperm		1 (2%)	2 (4%)	
Inflammation	4 (8%)		1 (2%)	4 (8%)
Preputial Gland	(50)	(50)	(50)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99028 - 06  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**  
 bis(2-Chloroethoxy)methane  
 CAS Number: 111-91-1

Date Report Requested: 08/26/2009  
 Time Report Requested: 13:44:13  
 First Dose M/F: 10/03/02 / 10/02/02  
 Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	150 MG/KG	300 MG/KG	600 MG/KG
Fibrosis			1 (2%)	
Inflammation	2 (4%)	3 (6%)	2 (4%)	1 (2%)
Duct, Ectasia	3 (6%)	4 (8%)		1 (2%)
Prostate	(50)	(50)	(50)	(50)
Atrophy	1 (2%)			
Inflammation	1 (2%)		2 (4%)	3 (6%)
Epithelium, Hyperplasia	16 (32%)	4 (8%)	3 (6%)	6 (12%)
Seminal Vesicle	(50)	(50)	(50)	(50)
Atrophy	1 (2%)			
Dilatation			1 (2%)	
Testes	(50)	(50)	(50)	(50)
Mineralization	1 (2%)	1 (2%)		
Germinal Epithelium, Degeneration	11 (22%)	7 (14%)	6 (12%)	9 (18%)
Interstitial Cell, Hyperplasia	1 (2%)			

**HEMATOPOIETIC SYSTEM**

Bone Marrow	(50)	(50)	(50)	(50)
Angiectasis		1 (2%)		
Atrophy	1 (2%)			
Hemorrhage	1 (2%)			2 (4%)
Myelofibrosis			1 (2%)	
Lymph Node	(2)	(1)	(2)	(1)
Lymph Node, Mandibular	(50)	(50)	(50)	(50)
Hyperplasia, Plasma Cell	1 (2%)	1 (2%)		2 (4%)
Lymph Node, Mesenteric	(50)	(50)	(50)	(49)
Hemorrhage	1 (2%)			2 (4%)
Hyperplasia, Lymphoid			1 (2%)	
Hyperplasia, Plasma Cell		1 (2%)		
Spleen	(50)	(50)	(50)	(50)
Atrophy	3 (6%)	1 (2%)	1 (2%)	1 (2%)
Hematopoietic Cell Proliferation			1 (2%)	1 (2%)
Thymus	(49)	(49)	(47)	(49)
Inflammation			1 (2%)	

**INTEGUMENTARY SYSTEM**

Mammary Gland	(1)	(0)	(0)	(0)
Duct, Dilatation	1 (100%)			
Skin	(50)	(50)	(50)	(50)
Ulcer	1 (2%)	1 (2%)		1 (2%)
Site Of Application - Dermis, Fibrosis	6 (12%)	1 (2%)	2 (4%)	25 (50%)
Site Of Application - Dermis, Inflammation	3 (6%)	1 (2%)	3 (6%)	13 (26%)
Site Of Application - Epidermis, Hyperplasia	8 (16%)	1 (2%)	4 (8%)	28 (56%)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99028 - 06  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**  
 bis(2-Chloroethoxy)methane  
 CAS Number: 111-91-1

Date Report Requested: 08/26/2009  
 Time Report Requested: 13:44:13  
 First Dose M/F: 10/03/02 / 10/02/02  
 Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	150 MG/KG	300 MG/KG	600 MG/KG
Site Of Application - Epidermis, Ulcer Subcutaneous Tissue, Edema	3 (6%)	1 (2%)	1 (2%)	4 (8%) 1 (2%)
<b>MUSCULOSKELETAL SYSTEM</b>				
Bone	(50)	(50)	(50)	(50)
Cartilage, Femur Joint, Hyperplasia	1 (2%)			
Femur, Joint, Inflammation	1 (2%)			
Skeletal Muscle	(0)	(0)	(0)	(1)
<b>NERVOUS SYSTEM</b>				
Brain	(50)	(50)	(50)	(50)
Ventricle, Inflammation	1 (2%)			
<b>RESPIRATORY SYSTEM</b>				
Lung	(50)	(50)	(50)	(50)
Inflammation	3 (6%)	3 (6%)		
Thrombosis		1 (2%)	1 (2%)	
Alveolar Epithelium, Hyperplasia	2 (4%)	1 (2%)	3 (6%)	2 (4%)
Alveolus, Infiltration Cellular, Histocyte	3 (6%)	1 (2%)		
Mediastinum, Inflammation		1 (2%)		
Perivascular, Cyst		1 (2%)		
Serosa, Hyperplasia		1 (2%)		
Nose	(50)	(50)	(50)	(50)
Inflammation	8 (16%)	3 (6%)	2 (4%)	3 (6%)
Respiratory Epithelium, Hyperplasia	1 (2%)		1 (2%)	
<b>SPECIAL SENSES SYSTEM</b>				
Eye	(50)	(50)	(50)	(50)
Arteriole, Inflammation	1 (2%)			
Cornea, Hyperplasia				1 (2%)
Cornea, Inflammation	3 (6%)			
Retrolbulbar, Inflammation	1 (2%)			
Harderian Gland	(50)	(50)	(50)	(49)
Cyst	1 (2%)			
Hemorrhage				1 (2%)
Epithelium, Hyperplasia			2 (4%)	
Zymbal's Gland	(1)	(0)	(0)	(1)
Cyst	1 (100%)			1 (100%)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99028 - 06  
Test Type: CHRONIC  
Route: SKIN APPLICATION  
Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
bis(2-Chloroethoxy)methane  
CAS Number: 111-91-1

Date Report Requested: 08/26/2009  
Time Report Requested: 13:44:13  
First Dose M/F: 10/03/02 / 10/02/02  
Lab: BAT

---

B6C3F1 MICE MALE	0 MG/KG	150 MG/KG	300 MG/KG	600 MG/KG
Inflammation	1 (100%)			

---

URINARY SYSTEM

Kidney	(50)	(50)	(50)	(50)
Cyst	7 (14%)	8 (16%)	11 (22%)	11 (22%)
Hydronephrosis	5 (10%)	1 (2%)	3 (6%)	1 (2%)
Infarct		1 (2%)	1 (2%)	
Infiltration Cellular, Mononuclear Cell		3 (6%)		
Inflammation	4 (8%)	2 (4%)	4 (8%)	1 (2%)
Mineralization	22 (44%)	26 (52%)	21 (42%)	25 (50%)
Nephropathy	45 (90%)	42 (84%)	44 (88%)	37 (74%)
Artery, Inflammation	2 (4%)		2 (4%)	
Urinary Bladder	(50)	(50)	(50)	(50)
Mineralization	1 (2%)			

---

\*\*\* END OF MALE \*\*\*

TDMS No. 99028 - 06  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
 bis(2-Chloroethoxy)methane  
 CAS Number: 111-91-1

Date Report Requested: 08/26/2009  
 Time Report Requested: 13:44:13  
 First Dose M/F: 10/03/02 / 10/02/02  
 Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	100 MG/KG	200 MG/KG	400 MG/KG
<b>Disposition Summary</b>				
Animals Initially in Study	50	50	50	50
Early Deaths				
Moribund Sacrifice	11	5	7	11
Natural Death	8	7	6	2
Survivors				
Natural Death				1
Terminal Sacrifice	31	38	37	36
Animals Examined Microscopically	50	50	50	50

ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(50)
Inflammation			1 (2%)	
Gallbladder	(50)	(50)	(50)	(50)
Fibrosis	1 (2%)			
Epithelium, Cyst				1 (2%)
Epithelium, Hyperplasia	1 (2%)			
Intestine Large, Cecum	(50)	(50)	(50)	(50)
Arteriole, Inflammation		1 (2%)		
Intestine Large, Colon	(50)	(50)	(50)	(50)
Arteriole, Inflammation		1 (2%)		
Epithelium, Diverticulum	1 (2%)			
Intestine Small, Duodenum	(50)	(50)	(50)	(50)
Arteriole, Inflammation		1 (2%)		
Intestine Small, Ileum	(50)	(50)	(50)	(50)
Inflammation		1 (2%)	1 (2%)	
Ulcer		1 (2%)		
Epithelium, Diverticulum		1 (2%)		
Intestine Small, Jejunum	(50)	(50)	(50)	(50)
Epithelium, Hyperplasia				1 (2%)
Peyer's Patch, Diverticulum	1 (2%)			
Peyer's Patch, Hyperplasia		2 (4%)		1 (2%)
Liver	(50)	(50)	(50)	(50)
Angiectasis			2 (4%)	2 (4%)
Basophilic Focus	1 (2%)	2 (4%)	2 (4%)	
Clear Cell Focus	1 (2%)	3 (6%)		5 (10%)
Eosinophilic Focus	12 (24%)	9 (18%)	11 (22%)	12 (24%)
Hematopoietic Cell Proliferation				1 (2%)
Infarct	1 (2%)			
Inflammation	8 (16%)	10 (20%)	15 (30%)	10 (20%)
Mitotic Alteration			1 (2%)	



TDMS No. 99028 - 06  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**  
 bis(2-Chloroethoxy)methane  
 CAS Number: 111-91-1

Date Report Requested: 08/26/2009  
 Time Report Requested: 13:44:13  
 First Dose M/F: 10/03/02 / 10/02/02  
 Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	100 MG/KG	200 MG/KG	400 MG/KG
Mixed Cell Focus	1 (2%)	1 (2%)		1 (2%)
Pigmentation, Hemosiderin			1 (2%)	1 (2%)
Regeneration		1 (2%)	1 (2%)	
Tension Lipidosis	7 (14%)	6 (12%)	5 (10%)	8 (16%)
Bile Duct, Cyst			1 (2%)	1 (2%)
Hepatocyte, Hypertrophy				1 (2%)
Hepatocyte, Mineralization	1 (2%)			
Hepatocyte, Necrosis	2 (4%)	4 (8%)	2 (4%)	3 (6%)
Hepatocyte, Vacuolization Cytoplasmic		1 (2%)		
Hepatocyte, Vacuolization Cytoplasmic, Diffuse	3 (6%)	1 (2%)	5 (10%)	3 (6%)
Serosa, Fibrosis	1 (2%)			1 (2%)
Serosa, Inflammation	2 (4%)	1 (2%)		
Mesentery	(16)	(13)	(11)	(10)
Inflammation			2 (18%)	2 (20%)
Necrosis	14 (88%)	13 (100%)	8 (73%)	7 (70%)
Pancreas	(50)	(50)	(50)	(50)
Basophilic Focus				2 (4%)
Inflammation	1 (2%)			
Acinus, Atrophy		2 (4%)		
Acinus, Hyperplasia	6 (12%)	3 (6%)	7 (14%)	9 (18%)
Arteriole, Inflammation				1 (2%)
Duct, Cyst	1 (2%)	2 (4%)		
Duct, Inflammation			1 (2%)	
Salivary Glands	(50)	(50)	(50)	(50)
Stomach, Forestomach	(50)	(50)	(50)	(50)
Inflammation	2 (4%)			
Ulcer	1 (2%)			
Epithelium, Hyperplasia	5 (10%)	5 (10%)	13 (26%)	5 (10%)
Stomach, Glandular	(50)	(50)	(50)	(50)
Mineralization		2 (4%)		
Epithelium, Cyst				1 (2%)
Epithelium, Hyperplasia	2 (4%)	1 (2%)	1 (2%)	
Glands, Cyst			1 (2%)	3 (6%)
Glands, Hyperplasia		2 (4%)		
Tooth	(0)	(0)	(2)	(3)
Dysplasia				2 (67%)
Inflammation			1 (50%)	
Gingiva, Hyperplasia				1 (33%)
Peridontal Tissue, Fibrosis				2 (67%)
Peridontal Tissue, Inflammation				1 (33%)
<b>CARDIOVASCULAR SYSTEM</b>				
Blood Vessel	(50)	(50)	(50)	(50)

TDMS No. 99028 - 06  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**  
 bis(2-Chloroethoxy)methane  
 CAS Number: 111-91-1

Date Report Requested: 08/26/2009  
 Time Report Requested: 13:44:13  
 First Dose M/F: 10/03/02 / 10/02/02  
 Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	100 MG/KG	200 MG/KG	400 MG/KG
Aorta, Inflammation		1 (2%)		
Heart	(50)	(50)	(50)	(50)
Artery, Inflammation	1 (2%)	3 (6%)	2 (4%)	1 (2%)
Atrium, Thrombosis			1 (2%)	1 (2%)
Epicardium, Inflammation				1 (2%)
Myocardium, Cardiomyopathy	10 (20%)	7 (14%)	10 (20%)	17 (34%)
Myocardium, Fibrosis	1 (2%)	1 (2%)		2 (4%)
Myocardium, Infiltration Cellular, Mononuclear Cell	9 (18%)	7 (14%)	10 (20%)	17 (34%)
Myocardium, Mineralization	1 (2%)	1 (2%)	1 (2%)	1 (2%)
Myocardium, Necrosis	1 (2%)			
Myocardium, Vacuolization Cytoplasmic	14 (28%)	4 (8%)	6 (12%)	13 (26%)
Valve, Thrombosis	1 (2%)			

**ENDOCRINE SYSTEM**

Adrenal Cortex	(50)	(50)	(50)	(50)
Angiectasis				1 (2%)
Atrophy	1 (2%)			
Hyperplasia	11 (22%)	11 (22%)	7 (14%)	11 (22%)
Hypertrophy	38 (76%)	46 (92%)	42 (84%)	40 (80%)
Subcapsular, Hyperplasia	50 (100%)	50 (100%)	50 (100%)	48 (96%)
Adrenal Medulla	(50)	(50)	(50)	(50)
Hyperplasia	6 (12%)	2 (4%)	7 (14%)	2 (4%)
Islets, Pancreatic	(50)	(50)	(50)	(50)
Hyperplasia	23 (46%)	23 (46%)	31 (62%)	21 (42%)
Pituitary Gland	(49)	(50)	(50)	(50)
Pars Distalis, Angiectasis	1 (2%)	2 (4%)		
Pars Distalis, Cyst	2 (4%)	1 (2%)	1 (2%)	3 (6%)
Pars Distalis, Hyperplasia	24 (49%)	27 (54%)	24 (48%)	27 (54%)
Pars Intermedia, Hyperplasia			1 (2%)	
Thyroid Gland	(50)	(50)	(50)	(50)
Inflammation	1 (2%)	1 (2%)		
C-cell, Hyperplasia			1 (2%)	
Follicle, Cyst	1 (2%)		1 (2%)	1 (2%)
Follicular Cell, Hyperplasia		2 (4%)	1 (2%)	1 (2%)

**GENERAL BODY SYSTEM**

None

**GENITAL SYSTEM**

TDMS No. 99028 - 06  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

bis(2-Chloroethoxy)methane

CAS Number: 111-91-1

Date Report Requested: 08/26/2009  
 Time Report Requested: 13:44:13  
 First Dose M/F: 10/03/02 / 10/02/02  
 Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	100 MG/KG	200 MG/KG	400 MG/KG
Clitoral Gland	(50)	(50)	(49)	(50)
Inflammation		1 (2%)	1 (2%)	
Ovary	(50)	(50)	(50)	(50)
Angiectasis		1 (2%)		
Cyst	13 (26%)	7 (14%)	7 (14%)	15 (30%)
Hemorrhage	2 (4%)	1 (2%)		3 (6%)
Mineralization		1 (2%)		
Pigmentation, Hemosiderin	1 (2%)			
Thrombosis				1 (2%)
Interstitial Cell, Hyperplasia				1 (2%)
Periovarian Tissue, Inflammation	2 (4%)			
Uterus	(50)	(50)	(50)	(50)
Hemorrhage				1 (2%)
Endometrium, Hyperplasia, Cystic	49 (98%)	47 (94%)	48 (96%)	50 (100%)
Myometrium, Angiectasis	1 (2%)			
Myometrium, Cyst				1 (2%)
Vagina	(0)	(0)	(1)	(0)
<b>HEMATOPOIETIC SYSTEM</b>				
Bone Marrow	(50)	(50)	(50)	(50)
Angiectasis			1 (2%)	
Myelofibrosis	8 (16%)	3 (6%)	8 (16%)	11 (22%)
Lymph Node	(8)	(9)	(3)	(5)
Iliac, Degeneration, Cystic	1 (13%)			
Iliac, Hemorrhage	1 (13%)			
Lumbar, Hyperplasia, Lymphoid	1 (13%)			
Pancreatic, Hyperplasia, Lymphoid		1 (11%)		
Renal, Hyperplasia, Lymphoid	1 (13%)			
Lymph Node, Mandibular	(50)	(50)	(50)	(49)
Infiltration Cellular, Plasma Cell				1 (2%)
Lymph Node, Mesenteric	(50)	(50)	(49)	(50)
Infiltration Cellular, Plasma Cell			1 (2%)	
Necrosis			1 (2%)	
Arteriole, Inflammation		1 (2%)		
Spleen	(50)	(50)	(50)	(50)
Hematopoietic Cell Proliferation	2 (4%)	1 (2%)	3 (6%)	1 (2%)
Hyperplasia, Lymphoid	1 (2%)	4 (8%)		1 (2%)
Infiltration Cellular, Plasma Cell			2 (4%)	
Capsule, Hyperplasia	1 (2%)			
Thymus	(50)	(50)	(50)	(50)
Atrophy			1 (2%)	
Hyperplasia, Lymphoid			1 (2%)	3 (6%)

TDMS No. 99028 - 06  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**  
 bis(2-Chloroethoxy)methane  
 CAS Number: 111-91-1

Date Report Requested: 08/26/2009  
 Time Report Requested: 13:44:13  
 First Dose M/F: 10/03/02 / 10/02/02  
 Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	100 MG/KG	200 MG/KG	400 MG/KG
<b>INTEGUMENTARY SYSTEM</b>				
Mammary Gland	(48)	(50)	(50)	(50)
Skin	(50)	(50)	(50)	(50)
Site Of Application - Dermis, Fibrosis	4 (8%)	1 (2%)		2 (4%)
Site Of Application - Dermis, Inflammation	4 (8%)	2 (4%)	1 (2%)	1 (2%)
Site Of Application - Epidermis, Hyperplasia	3 (6%)	1 (2%)	3 (6%)	3 (6%)
Site Of Application - Epidermis, Ulcer	1 (2%)		1 (2%)	
<b>MUSCULOSKELETAL SYSTEM</b>				
Bone	(50)	(50)	(50)	(50)
<b>NERVOUS SYSTEM</b>				
Brain	(50)	(50)	(50)	(50)
Spinal Cord	(2)	(0)	(1)	(0)
Demyelination	1 (50%)		1 (100%)	
<b>RESPIRATORY SYSTEM</b>				
Lung	(50)	(50)	(50)	(50)
Hemorrhage	1 (2%)			
Infiltration Cellular		1 (2%)		
Inflammation	1 (2%)	1 (2%)		1 (2%)
Alveolar Epithelium, Hyperplasia	5 (10%)	1 (2%)	4 (8%)	4 (8%)
Alveolus, Infiltration Cellular, Histiocyte	1 (2%)	1 (2%)		2 (4%)
Arteriole, Inflammation		1 (2%)		
Serosa, Hyperplasia				1 (2%)
Nose	(50)	(50)	(50)	(50)
Inflammation	13 (26%)	8 (16%)	7 (14%)	6 (12%)
Polyp, Inflammatory			1 (2%)	
Glands, Olfactory Epithelium, Dilatation	1 (2%)		1 (2%)	
Glands, Respiratory Epithelium, Dilatation		1 (2%)	1 (2%)	
Respiratory Epithelium, Hyperplasia				2 (4%)
Septum, Cyst			1 (2%)	
Pleura	(0)	(0)	(1)	(0)
<b>SPECIAL SENSES SYSTEM</b>				
Eye	(50)	(50)	(50)	(50)
Cornea, Inflammation		2 (4%)		

TDMS No. 99028 - 06  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

bis(2-Chloroethoxy)methane

CAS Number: 111-91-1

Date Report Requested: 08/26/2009  
 Time Report Requested: 13:44:13  
 First Dose M/F: 10/03/02 / 10/02/02  
 Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	100 MG/KG	200 MG/KG	400 MG/KG
Retina, Dysplasia			1 (2%)	1 (2%)
Harderian Gland	(50)	(50)	(50)	(50)
Epithelium, Hyperplasia	12 (24%)	7 (14%)	6 (12%)	4 (8%)
<b>URINARY SYSTEM</b>				
Kidney	(50)	(50)	(50)	(50)
Infarct	1 (2%)	1 (2%)	3 (6%)	3 (6%)
Infiltration Cellular, Mononuclear Cell	4 (8%)	1 (2%)	1 (2%)	1 (2%)
Inflammation	4 (8%)			
Mineralization	9 (18%)	8 (16%)	11 (22%)	9 (18%)
Nephropathy	37 (74%)	37 (74%)	42 (84%)	38 (76%)
Capsule, Fibrosis	1 (2%)			
Renal Tubule, Dilatation		1 (2%)		
Renal Tubule, Pigmentation		1 (2%)		
Urinary Bladder	(50)	(50)	(50)	(50)
Amyloid Deposition				1 (2%)
Hyperplasia, Lymphoid				1 (2%)
Inflammation				1 (2%)
Inflammation, Chronic	1 (2%)			
Arteriole, Inflammation			1 (2%)	
Arteriole, Muscularis, Degeneration		1 (2%)		

\*\*\* END OF REPORT \*\*\*